Buprenorphine Coverage Is Improving, but Access Barriers Remain
-
Jun 08, 2023
Although health plans’ formularies have largely been making it easier for people to access buprenorphine in recent years, new research indicates that coverage barriers and access gaps remain — particularly for a newer, costlier extended-release formulation of the opioid use disorder (OUD) drug.
However, a recent FDA approval could usher in more competition that decreases the price and increases coverage of extended-release buprenorphine, which has major advantages over the immediate-release versions, according to one of the study authors.
Read more© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.